Our results strongly suggest that H3.3 K27M acts in an analogous manner and blocks differentiation by disrupting PML-NBs, meaning that ATO may also be effective at overriding these PML-NB defects and promote cell death in H3.3-mutated gliomas. The gene discussed is PML; the disease is central nervous system cancer.